Year: 2025
Type: article
Abstract: Despite multiple therapies that delay disease progression and prolong life, metastatic castration-resistant prostate cancer (mCRPC) remains the second leading cause of cancer related death in American men [ 1 , 2 ]. Radioligand therapy (RLT) targeting Prostate Specific Membrane Antigen (PSMA) has been shown to improve clinical outcomes and have a favorable safety profile [ 3 , 4 , 5 , 6 , 7 ]. In the Phase 3 VISION study, 177 Lu-PSMA-617 (vipivotide, Pluvicto, Novartis) was shown to prolong overall survival (OS) and improve quality of life in patients with mCRPC relative to best supportive care [ 5 , 7 ], while the Phase 2 TheraP Trial demonstrated that 177 Lu-PSMA-617 resulted in a higher rate of PSA decline relative to cabazitaxel chemotherapy [ 6 ].
Source: EJNMMI Research
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
Funder: National Cancer Institute
OpenAlex ID: W4409211509